Raloxifene slows atherosclerosis?

Article

The selective estrogen receptor modulator raloxifene lowers the risk of intima-media thickness (IMT) progression in postmenopausal women by about 40%.

The selective estrogen receptor modulator raloxifene lowers the risk of intima-media thickness (IMT) progression in postmenopausal women by about 40%, according to the results of a recent prospective study.

The study involved 155 healthy postmenopausal women who received either raloxifene 60 mg/d or placebo for 18 months.

Not only was the progression slope of carotid IMT more favorable in the raloxifene group than in the placebo group (0.0112 mm/18 mo vs. 0.0857 mm/18 mo, respectively; P<0.004), but the women taking raloxifene experienced significant decreases in plasma triglycerides (P<0.02), low-density lipoprotein cholesterol (P<0.02), soluble forms of intercellular adhesion molecule-1 (P<0.005) and vascular cell adhesion molecule-1 (P<0.04), E-selectin (P<0.02), interleukin-6 (P<0.005), tumor necrosis factor α (P<0.005) levels, and in the homeostatic model assessment index (P<0.005), and a significant increase in plasma adiponectin levels (P<0.001).

Newsletter

Get the latest clinical updates, case studies, and expert commentary in obstetric and gynecologic care. Sign up now to stay informed.

Recent Videos
Michael Ussher, PhD, highlights the benefits of vaping over smoking in pregnancy | Image Credit: sgul.ac.uk.
Neal Barnard, MD, FACC, highlights AMA's new breast cancer prevention guidelines | Image Credit: pcrm.org.
Zachary Wagner, PhD, discusses the harms of bias in reproductive care | Image Credit: ornsife.usc.edu.
Related Content
© 2025 MJH Life Sciences

All rights reserved.